Back to antidote fact sheets
Print Friendly, PDF & Email
Fact sheet header Fact sheet header

Levocarnitine

Presentation

1g/5mL ampoule

*SAS*

Role

As an adjunct in the treatment of severe sodium valproate toxicity evidenced by valproate concentration > 850 mg/L or cardiovascular collapse and worsening acidaemia.

Levocarnitin
  • ALERT – Consultation with a clinical toxicologist is recommended through the local toxicology service or Poisons Information Centre 13 11 26.

Dose

  • 100mg/kg IV loading dose (max 6g); then
  • 50mg/kg Q8H (max 3g)

Stocking recommendations

Tertiary centre Regional centre Rural centre Remote centre

10 vials

10 vials 0 vials 0 vials

Rationale

The role of L-carnitine in valproate toxicity is controversial. It reduces the production of a toxic metabolite, but whether this leads to improved outcomes is unclear. Given it is a low cost, safe therapy with scientific plausibility, it is recommended in cases of severe toxicity. Patients with severe valproate toxicity will need to be managed in facilities with haemodialysis. Initiation of L-carnitine therapy can be delayed until transfer to a dialysis centre has occurred.

Disclaimer

Fact sheet developed by Queensland Poisons Information Centre, Updated: July 2020.

This fact sheet is about the use of these antidotes in Australia, and may not apply to other countries. Children’s Health Queensland Hospital and Health Service cannot be held responsible for the accuracy of information, omissions of information, or any actions that may be taken as a consequence of reading this fact sheet.

CHQ